Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Associations of Cyclooxygenase 2 Polymorphic Genotypes with Bladder Cancer Risk in Taiwan

WEN-SHIN CHANG, CHIA-WEN TSAI, HONG-XUE JI, HSI-CHIN WU, YI-TING CHANG, CHI-SHUN LIEN, WEN-LING LIAO, WU-CHUNG SHEN, CHANG-HAI TSAI and DA-TIAN BAU
Anticancer Research December 2013, 33 (12) 5401-5405;
WEN-SHIN CHANG
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIA-WEN TSAI
2Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HONG-XUE JI
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
4Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HSI-CHIN WU
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YI-TING CHANG
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
4Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHI-SHUN LIEN
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
5Department of Urology, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WEN-LING LIAO
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WU-CHUNG SHEN
4Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHANG-HAI TSAI
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DA-TIAN BAU
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
2Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: Bladder cancer is the sixth most common cancer worldwide and its incidence is particularly high in southwestern Taiwan. However, the genetic contribution to its etiology is not well-understood. The aim of this study is to evaluate the association of cyclooxygenase 2 (Cox-2) polymorphic genotypes with Taiwan bladder cancer patients. Materials and Methods: Six polymorphic variants of Cox-2 were analyzed regarding their association with bladder cancer risk, and three hundred and seventy-five patients with bladder cancer and same amount of age- and gender-matched healthy controls recruited were genotyped by the PCR-RFLP method. Results: Among the six polymorphic sites examined, only the Cox-2 promoter G-765C (rs20417) genotypes were positively associated with bladder cancer risk (p=0.0102). Individuals with the Cox-2 -765GC genotypes were associated with higher prostate cancer risk than those with -765GG. Conclusion: Our findings provide evidence that the C allele of Cox-2 promoter G-765C may be associated with the overexpression of COX-2 during bladder cancer development and may be a useful marker for the early detection of bladder cancer.

  • Cox-2
  • polymorphism
  • bladder cancer
  • genotype

Bladder cancer is the most serious urinary neoplasm worldwide. In the western countries, bladder cancer is the fourth most common cancer among males, accounting for 7% of the total malignancies (1). In Taiwan, bladder cancer ranks seventh in incidence and mortality among common carcinomas (2). Carcinogenesis of bladder cancer is a complex, multi-step and multi-factorial process resulting following interactions of both environmental and genetic factors. In literature, the environmental risk factors for bladder carcinogenesis may include cigarette smoking, carcinogenic aromatic amine exposure and harmful drug consumption, such as phenacetine, chlornaphrazine and cyclophosphamide (3, 4).

Cyclooxygenases (also known as prostaglandin endoperoxide synthases, PTGSs) are key enzymes that convert arachidonic acids to prostaglandin H2 (5). There are two forms of cyclooxygenases, Cox-1 and Cox-2. Cox-1 is a housekeeping enzyme involved in intracellular signaling, whereas Cox-2 is absent from many cell types unless induced by tumor promoters, growth factors, or cytokines (6-8). Accumulating evidence has shown that up-regulation of Cox-2 is closely-associated with malignant progression (9-12). Evidence collected from mRNA and protein levels of Cox-2 showed that levels may vary dramatically among the investigated subjects, and the variation may be partially determined by genetic variations, such as single nucleotide polymorphisms (SNPs) of Cox-2 itself (13, 14).

In literature, the association between SNPs of Cox-2 and bladder cancer susceptibility has been examined in Korean (15), New England (16), and India (17) populations, however, never among the Taiwanese. The present work is focused in two purposes, one is to perform the large case-control genotyping study of bladder cancer in Taiwan, a highly genetically-conserved population; the other is to examine the biological plausibility that genetic variation of Cox-2 could alter its coded enzyme expression levels or biochemical function and consequently have an impact on modifying the individual risk for bladder cancer. To examine the above hypothesis that the SNP variants of Cox-2 are associated with the risk of bladder cancer, the genetic polymorphisms of six Cox-2 SNPs, including G-1195A (rs689466), G-765C (rs20417), T+8473C (rs5275), intron 1 (rs2745557), intron 5 (rs16825748), and intron 6 (rs2066826), were analyzed in a Taiwanese population (control/case; 375/375).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Primer sequences, PCR and restriction fragment length polymorphism (RFLP) conditions for the Cox-2 genotyping.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Characteristics of bladder cancer patients and non-cancer healthy controls.

Materials and Methods

Study population and sample collection. Three hundred and seventy-five patients diagnosed with bladder cancer were recruited at the outpatient clinics of general surgery between 2003-2009 at the China Medical University Hospital, Taichung, Taiwan, Republic of China. All patients who voluntarily participated, completed a self-administered questionnaire and provided peripheral blood samples. As many non-bladder cancer healthy controls were selected by matching for age and gender after initial random sampling from the Health Examination Cohort of the hospital. Exclusion criteria for the control group included previous malignancy, metastasized cancer from other or unknown origin, and any familial or genetic diseases. In addition, all members in the two groups completed a short questionnaire.

Genotyping assays. Genomic DNA was prepared from peripheral blood leukocytes of each subject using a QIAamp Blood Mini Kit (Blossom, Taipei, Taiwan) and further processed as previous genotyping studies (18-21). The polymerase chain reaction (PCR) cycling conditions for all the six genotyping work were: one cycle at 94°C for 5 min; 35 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 30 sec, and a final extension at 72°C for 10 min. The PCR primer sequences and restriction enzyme for each DNA product are listed in Table I.

Statistical analyses. To ensure that the controls used were representative of the general population, and to exclude the possibility of genotyping error, the deviation of the genotype frequencies of Cox-2 SNPs in the controls from those expected under the Hardy-Weinberg equilibrium was assessed using the goodness-of-fit test. Pearson's chi-square test or Fisher's exact test (when the number in any cell was less than five) was used to compare the distribution of the genotypes between cases and controls. Data were deemed significant when p<0.05. Cancer risk associated with the genotypes was estimated as odds ratios (ORs) and 95% confidence intervals (95%CIs) using unconditioned logistic regression.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Distribution of Cox-2 genotypes among bladder cancer patient and control subjects.

Results

The frequency distributions for age, gender, cigarette smoking and alcohol drinking habits of the 375 bladder cancer patients and 375 controls are shown in Table II. The characteristics of the patients and controls were all well-matched. None of the differences in these characteristics between both groups were statistically significant (p>0.05) (Table II).

The distribution of genotypic frequencies for the Cox-2 SNPs in controls and bladder cancer patients are shown in Table III. The genotypic frequencies of Cox-2 promoter G-765C polymorphism were differentially distributed between bladder cancer and control groups (p=0.0102), while those for other five polymorphisms were not significant, (p>0.05) (Table III). In detail, compared to those with GG, patients with the GC genotype may have 1.63-fold OR of bladder cancer susceptibility (95%CI=1.13-2.35).

The frequencies of the alleles for Cox-2 SNPs in controls and bladder cancer patients are shown in Table IV. The C allele of the Cox-2 promoter G-765C polymorphism was found to be associated with bladder cancer (p=0.0123). Compared to those with the G allele, genotypes with C allele at Cox-2 promoter G-765C may have 1.55-fold higher OR for bladder cancer susceptibility (95%CI=1.09-2.18). Thus, from the data in Tables III and IV it can be concluded that the Cox-2 promoter -765G allele appears to be associated with higher risk for bladder cancer in Taiwan, while the other Cox-2 genotypes investigated in this study do not.

Discussion

In recent literature, several studies have demonstrated that variant genotypes in Cox-2 were associated with the risk of prostate cancer (22-27). However, there is no article investigating its association with bladder cancer.

In the present study one variant, GC genotype of G-765C (rs20417) was associated with an increased risk of bladder cancer among Taiwanese, while no other variant did (Table III). In the allelic frequency analysis, the C allele was found to be associated with a higher risk of bladder cancer (Table IV). We have summarized findings of the present study along with those of other reports regarding prostate cancer in Table V. These findings are of pioneer significance for other groups to investigate its contribution in other populations. As for ourselves, further studies with larger population groups and the detail mechanisms are warranted, and should be compared with updated multi-ethnic studies to elucidate the role of Cox-2 in bladder cancer. Furthermore, sophisticated gene-gene and gene-environment interactions together with the contribution of Cox-2 genotype to prognosis of bladder cancer patients may be looked upon in the near future.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Cox-2 Allelic frequencies among bladder cancer patient and control subjects.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Summary of current and previous studies on the association of Cox-2 G-765C (rs20417) polymorphism and bladder/prostate cancer risk.

To sum up, this is the first study to demonstrate that a genetic variation in Cox-2 may influence the risk of bladder cancer. The presence of the C allele of promoter -765 was found to be associated with a higher risk of bladder cancer and this finding supports previous reports showing an association between Cox-2 variants and urinary cancer risk (23-27). We have provided evidence for a potent biomarker for bladder cancer early detection in Taiwanese and potentially for other countries.

Acknowledgements

The Authors appreciate Chieh-Lun Hsiao, Chia-En Miao, Lin-Lin Hou, Chao-Yi Lai, Tsai-Ping Ho and the Tissue Bank at the China Medical University for their technical assistance. This study was supported by research grants from the Terry Fox Cancer Research Foundation.

Footnotes

  • ↵* These Authors contributed equally to this work.

  • Received October 30, 2013.
  • Revision received November 9, 2013.
  • Accepted November 12, 2013.
  • Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Franekova M,
    2. Halasova E,
    3. Bukovska E,
    4. Luptak J,
    5. Dobrota D
    : Gene polymorphisms in bladder cancer. Urol Oncol 26: 1-8, 2008.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Wang YH,
    2. Lee YH,
    3. Tseng PT,
    4. Shen CH,
    5. Chiou HY
    : Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol 134: 203-209, 2008.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Steineck G,
    2. Wiholm BE,
    3. Gerhardsson de Verdier M
    : Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. Acta Oncol 34: 741-748, 1995.
    OpenUrlPubMed
  4. ↵
    1. Cohen SM,
    2. Shirai T,
    3. Steineck G
    : Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl: 105-115, 2000.
  5. ↵
    1. DeWitt DL
    : Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1083: 121-134, 1991.
    OpenUrlPubMed
  6. ↵
    1. Kujubu DA,
    2. Reddy ST,
    3. Fletcher BS,
    4. Herschman HR
    : Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. J Biol Chem 268: 5425-5430, 1993.
    OpenUrlAbstract/FREE Full Text
    1. Kawata R,
    2. Reddy ST,
    3. Wolner B,
    4. Herschman HR
    : Prostaglandin synthase 1 and prostaglandin synthase 2 both participate in activation-induced prostaglandin D2 production in mast cells. J Immunol 155: 818-825, 1995.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Reddy ST,
    2. Herschman HR
    : Ligand-induced prostaglandin synthesis requires expression of the TIS10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 269: 15473-15480, 1994.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Fujimura T,
    2. Ohta T,
    3. Oyama K,
    4. Miyashita T,
    5. Miwa K
    : Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol 12: 1336-1345, 2006.
    OpenUrlPubMed
    1. Marshall SF,
    2. Bernstein L,
    3. Anton-Culver H,
    4. Deapen D,
    5. Horn-Ross PL,
    6. Mohrenweiser H,
    7. Peel D,
    8. Pinder R,
    9. Purdie DM,
    10. Reynolds P,
    11. Stram D,
    12. West D,
    13. Wright WE,
    14. Ziogas A,
    15. Ross RK
    : Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97: 805-812, 2005.
    OpenUrlAbstract/FREE Full Text
    1. van Rees BP,
    2. Ristimaki A
    : Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol 36: 897-903, 2001.
    OpenUrlPubMed
  9. ↵
    1. Wang W,
    2. Bergh A,
    3. Damber JE
    : Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11: 3250-3256, 2005.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Cok SJ,
    2. Morrison AR
    : The 3’-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 276: 23179-23185, 2001.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Papafili A,
    2. Hill MR,
    3. Brull DJ,
    4. McAnulty RJ,
    5. Marshall RP,
    6. Humphries SE,
    7. Laurent GJ
    : Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22: 1631-1636, 2002.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kang S,
    2. Kim YB,
    3. Kim MH,
    4. Yoon KS,
    5. Kim JW,
    6. Park NH,
    7. Song YS,
    8. Kang D,
    9. Yoo KY,
    10. Kang SB,
    11. Lee HP
    : Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett 217: 11-16, 2005.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Baris D,
    2. Karagas MR,
    3. Koutros S,
    4. Colt JS,
    5. Johnson A,
    6. Schwenn M,
    7. Fischer AH,
    8. Figueroa JD,
    9. Berndt SI,
    10. Han S,
    11. Beane Freeman LE,
    12. Lubin JH,
    13. Cherala S,
    14. Cantor KP,
    15. Jacobs K,
    16. Chanock S,
    17. Chatterjee N,
    18. Rothman N,
    19. Silverman DT
    : Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern New England. Int J Cancer 132: 162-173, 2013.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Gangwar R,
    2. Mandhani A,
    3. Mittal RD
    : Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery 149: 126-134, 2011.
    OpenUrlPubMed
  15. ↵
    1. Hsia TC,
    2. Tsai CW,
    3. Liang SJ,
    4. Chang WS,
    5. Lin LY,
    6. Chen WC,
    7. Tu CY,
    8. Tsai CH,
    9. Bau DT
    : Effects of ataxia telangiectasia mutated (ATM) genotypes and smoking habits on lung cancer risk in Taiwan. Anticancer Res 33: 4067-4071, 2013.
    OpenUrlAbstract/FREE Full Text
    1. Tsai CW,
    2. Tsai MH,
    3. Shih LC,
    4. Chang WS,
    5. Lin CC,
    6. Bau DT
    : Association of interleukin-10 (IL10) promoter genotypes with nasopharyngeal carcinoma risk in Taiwan. Anticancer Res 33: 3391-3396, 2013.
    OpenUrlAbstract/FREE Full Text
    1. Chang WS,
    2. Ke HL,
    3. Tsai CW,
    4. Lien CS,
    5. Liao WL,
    6. Lin HH,
    7. Lee MH,
    8. Wu HC,
    9. Chang CH,
    10. Chen CC,
    11. Lee HZ,
    12. Bau DT
    : The role of XRCC6 T-991C functional polymorphism in renal cell carcinoma. Anticancer Res 32: 3855-3860, 2012.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Chang WS,
    2. Yang MD,
    3. Tsai CW,
    4. Cheng LH,
    5. Jeng LB,
    6. Lo WC,
    7. Lin CH,
    8. Huang CY,
    9. Bau DT
    : Association of cyclooxygenase 2 single-nucleotide polymorphisms and hepatocellular carcinoma in Taiwan. Chin J Physiol 55: 1-7, 2012.
    OpenUrlPubMed
  17. ↵
    1. Cheng I,
    2. Liu X,
    3. Plummer SJ,
    4. Krumroy LM,
    5. Casey G,
    6. Witte JS
    : COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97: 557-561, 2007.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Panguluri RC,
    2. Long LO,
    3. Chen W,
    4. Wang S,
    5. Coulibaly A,
    6. Ukoli F,
    7. Jackson A,
    8. Weinrich S,
    9. Ahaghotu C,
    10. Isaacs W,
    11. Kittles RA
    : COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25: 961-966, 2004.
    OpenUrlAbstract/FREE Full Text
    1. Shahedi K,
    2. Lindstrom S,
    3. Zheng SL,
    4. Wiklund F,
    5. Adolfsson J,
    6. Sun J,
    7. Augustsson-Balter K,
    8. Chang BL,
    9. Adami HO,
    10. Liu W,
    11. Gronberg H,
    12. Xu J
    : Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119: 668-672, 2006.
    OpenUrlCrossRefPubMed
    1. Fernandez P,
    2. de Beer PM,
    3. van der Merwe L,
    4. Heyns CF
    : COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis 29: 2347-2350, 2008.
    OpenUrlAbstract/FREE Full Text
    1. Wu HC,
    2. Chang CH,
    3. Ke HL,
    4. Chang WS,
    5. Cheng HN,
    6. Lin HH,
    7. Wu CY,
    8. Tsai CW,
    9. Tsai RY,
    10. Lo WC,
    11. Bau DT
    : Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in taiwan. Anticancer Res 31: 221-225, 2011.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Mandal RK,
    2. Mittal RD
    : Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort. Arch Med Res 42: 620-626, 2011.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 33 (12)
Anticancer Research
Vol. 33, Issue 12
December 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Associations of Cyclooxygenase 2 Polymorphic Genotypes with Bladder Cancer Risk in Taiwan
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Associations of Cyclooxygenase 2 Polymorphic Genotypes with Bladder Cancer Risk in Taiwan
WEN-SHIN CHANG, CHIA-WEN TSAI, HONG-XUE JI, HSI-CHIN WU, YI-TING CHANG, CHI-SHUN LIEN, WEN-LING LIAO, WU-CHUNG SHEN, CHANG-HAI TSAI, DA-TIAN BAU
Anticancer Research Dec 2013, 33 (12) 5401-5405;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Associations of Cyclooxygenase 2 Polymorphic Genotypes with Bladder Cancer Risk in Taiwan
WEN-SHIN CHANG, CHIA-WEN TSAI, HONG-XUE JI, HSI-CHIN WU, YI-TING CHANG, CHI-SHUN LIEN, WEN-LING LIAO, WU-CHUNG SHEN, CHANG-HAI TSAI, DA-TIAN BAU
Anticancer Research Dec 2013, 33 (12) 5401-5405;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Association of Matrix Metalloproteinase-1 Genotypes With Bladder Cancer Risk
  • Association of Nijmegen Breakage Syndrome 1 Genotypes With Bladder Cancer Risk
  • Association of Caspase-8 Genotypes With Bladder Cancer Risk
  • Association of Matrix Metalloproteinase-8 Genotypes with the Risk of Bladder Cancer
  • Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer
  • Association of Enhancer of Zeste 2 (EZH2) Genotypes with Bladder Cancer Risk in Taiwan
  • Significant Association of Cyclo-oxygenase 2 Genotypes with Upper Tract Urothelial Cancer
  • Evaluation of the Contribution of Cyclooxygenase 2 Genotypes to Breast Cancer in Taiwan
  • The Role of Functional Polymorphisms of Cyclooxygenase 2 in Renal Cell Carcinoma
  • Evaluation of the Contribution of Methylenetetrahydrofolate Reductase Genotypes to Taiwan Breast Cancer
  • Significant Association of Interleukin-10 Genotypes and Oral Cancer Susceptibility in Taiwan
  • Contribution of DNA Double-strand Break Repair Gene XRCC3 Genotypes to Oral Cancer Susceptibility in Taiwan
  • A Novel Caveolin-1 Biomarker for Clinical Outcome of Sarcopenia
  • Association of Caveolin-1 Genotypes with Gastric Cancer in Taiwan
  • Google Scholar

More in this TOC Section

  • PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer
  • Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma
  • Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance via Inhibition of RAF Dimerization in PLX4032-resistant Melanoma
Show more Experimental Studies

Similar Articles

Keywords

  • COX-2
  • polymorphism
  • bladder cancer
  • genotype
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire